Inactive Instrument

Company DIUL GROUP

Equities

DNL

GB00BDB6Q760

Business Summary

Diurnal Group plc is a specialty pharmaceutical company. It is focused on developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. It focuses on addressing unmet clinical and patient needs in hormone replacement by developing and marketing products for the rare and orphan diseases Congenital Adrenal Hyperplasia (CAH) and Adrenal Insufficiency (AI). The Company's products include Alkindi and Efmody. Its product Alkindi (hydrocortisone granules in capsules for opening) is a specifically designed for young children suffering from paediatric AI, and the related condition CAH. Its product Efmody (modified-release hydrocortisone) provides a drug release profile that is designed to improve disease treatment for adults with CAH, as measured by androgen (male sex hormone) control. Its pipeline includes DNL-0200, DNL-0300, DNL-0400 and DNL-0500.

Number of employees: 33

Managers

Managers TitleAgeSince
Chief Executive Officer 55 17-01-12
Chief Operating Officer - -
Chief Tech/Sci/R&D Officer 53 -
Corporate Officer/Principal - 21-10-31

Members of the board

Members of the board TitleAgeSince
Chief Executive Officer 55 17-01-12
Director/Board Member 73 15-11-30

Company contact information

Diurnal Group Ltd.

Cardiff Medicentre Heath Park

CF14 4UJ, Cardiff

+44 29 2068 2069

http://www.diurnal.co.uk
address DIUL GROUP(DNL)

Sector

This company's sector is not yet available